Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (271-280 of 461) with videos related to

Pageof 47
Sort By:
The American Journal of Psychiatry|June 1, 1989
Hypersensitivity to carbon dioxide in panic disorderL A Papp, R Goetz, R Cole, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2015
Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINEK A Papp, K Barber, R Bissonnette, et al.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.
Dermatology and Therapy|March 6, 2020
Correction to: Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)Kim A Papp, Sascha Gerdes, Craig L Leonardi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 18, 2013
Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III studyK A Papp, M Sundaram, Y Bao, et al.
Journal of Psychiatric Research|January 1, 1988
Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further researchM R Liebowitz, A J Fyer, J M Gorman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2018
Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trialK A Papp, A Blauvelt, A B Kimball, et al.
Psychiatry Research|August 1, 1989
Do panic disorder patients indiscriminately endorse somatic complaints?R R Goetz, J M Gorman, D J Dillon, et al.
Pageof 47

Showing results (271-280 of 461) with videos related to

Sort By:
Pageof 47
The American Journal of Psychiatry|June 1, 1989
Hypersensitivity to carbon dioxide in panic disorderL A Papp, R Goetz, R Cole, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2015
Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINEK A Papp, K Barber, R Bissonnette, et al.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.
Dermatology and Therapy|March 6, 2020
Correction to: Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)Kim A Papp, Sascha Gerdes, Craig L Leonardi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 18, 2013
Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III studyK A Papp, M Sundaram, Y Bao, et al.
Journal of Psychiatric Research|January 1, 1988
Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further researchM R Liebowitz, A J Fyer, J M Gorman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2018
Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trialK A Papp, A Blauvelt, A B Kimball, et al.
Psychiatry Research|August 1, 1989
Do panic disorder patients indiscriminately endorse somatic complaints?R R Goetz, J M Gorman, D J Dillon, et al.
Pageof 47